1. Cell Biology
  2. Chromosomes and Gene Expression
Download icon

Vasohibin1, a new mouse cardiomyocyte IRES trans-acting factor that regulates translation during early hypoxia

  1. Fransky Hantelys
  2. Anne-Claire Godet
  3. Florian David
  4. Florence Tatin
  5. Edith Renaud-Gabardos
  6. Françoise Pujol
  7. Leila H Diallo
  8. Isabelle Ader
  9. Laetitia Ligat
  10. Anthony K Henras
  11. Yasufumi Sato
  12. Angelo Parini
  13. Eric Lacazette
  14. Barbara Garmy-Susini
  15. Anne-Catherine Prats  Is a corresponding author
  1. Inserm UMR 1048, France
  2. Inserm U1031, France
  3. Inserm UMR 1037, France
  4. Université Paul Sabatier, France
  5. Tohoku Universtiy, Japan
Research Article
  • Cited 9
  • Views 1,080
  • Annotations
Cite this article as: eLife 2019;8:e50094 doi: 10.7554/eLife.50094

Abstract

Hypoxia, a major inducer of angiogenesis, triggers major changes of gene expression at the transcriptional level. Furthermore, global protein synthesis is blocked while internal ribosome entry sites (IRES) allow specific mRNAs to be translated. Here we report the transcriptome and translatome signatures of (lymph)angiogenic genes in hypoxic HL-1 mouse cardiomyocytes: most genes are induced at the translatome level, including all IRES-containing mRNAs. Our data reveal activation of (lymph)angiogenic factor mRNA IRESs in early hypoxia. We identify vasohibin1 (VASH1) as an IRES trans-acting factor (ITAF) able to bind RNA and to activate the FGF1 IRES in hypoxia while it tends to inhibit several IRESs in normoxia. VASH1 depletion has also a wide impact on the translatome of (lymph)angiogenesis genes, suggesting that this protein can regulate translation positively or negatively in early hypoxia. Translational control thus appears as a pivotal process to trigger new vessel formation in ischemic heart.

Data availability

All data generated or analysed during this study are included in the manuscript and supporting files. Lentivector plasmid complete maps and sequences are available on Dryad.

The following data sets were generated

Article and author information

Author details

  1. Fransky Hantelys

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  2. Anne-Claire Godet

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  3. Florian David

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  4. Florence Tatin

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  5. Edith Renaud-Gabardos

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  6. Françoise Pujol

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  7. Leila H Diallo

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  8. Isabelle Ader

    Stromalab, Inserm U1031, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  9. Laetitia Ligat

    CRCT, Inserm UMR 1037, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  10. Anthony K Henras

    Centre de Biologie Intégrative, Université Paul Sabatier, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  11. Yasufumi Sato

    Department of Vascular Biology, Institute of Development, Aging and Cancer, Tohoku Universtiy, Sendai, Japan
    Competing interests
    The authors declare that no competing interests exist.
  12. Angelo Parini

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  13. Eric Lacazette

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  14. Barbara Garmy-Susini

    I2MC, Inserm UMR 1048, Toulouse, France
    Competing interests
    The authors declare that no competing interests exist.
  15. Anne-Catherine Prats

    I2MC, Inserm UMR 1048, Toulouse, France
    For correspondence
    anne-catherine.prats@inserm.fr
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5282-3776

Funding

Region Midi-Pyrenees

  • Anne-Catherine Prats

AFM-Téléthon

  • Edith Renaud-Gabardos
  • Anne-Catherine Prats

Association pour la Recherche sur le Cancer

  • Anne-Catherine Prats

European Commission (REFBIO VEMT)

  • Anne-Catherine Prats

Fondation Toulouse Cancer-Sante

  • Barbara Garmy-Susini

Agence Nationale de la Recherche (ANR-18-CE11-0020-RIBOCARD)

  • Anne-Catherine Prats

Ligue Contre le Cancer

  • Fransky Hantelys
  • Anne-Claire Godet

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Reviewing Editor

  1. Nahum Sonenberg, McGill University, Canada

Publication history

  1. Received: July 18, 2019
  2. Accepted: December 9, 2019
  3. Accepted Manuscript published: December 9, 2019 (version 1)
  4. Version of Record published: January 7, 2020 (version 2)

Copyright

© 2019, Hantelys et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,080
    Page views
  • 189
    Downloads
  • 9
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Download citations (links to download the citations from this article in formats compatible with various reference manager tools)

Open citations (links to open the citations from this article in various online reference manager services)

Further reading

    1. Cell Biology
    Joël Lemière et al.
    Research Article

    During clathrin-mediated endocytosis in eukaryotes, actin assembly is required to overcome large membrane tension and turgor pressure. However, the molecular mechanisms by which the actin machinery adapts to varying membrane tension remain unknown. In addition, how cells reduce their membrane tension when they are challenged by hypotonic shocks remains unclear. We used quantitative microscopy to demonstrate that cells rapidly reduce their membrane tension using three parallel mechanisms. In addition to using their cell wall for mechanical protection, yeast cells disassemble eisosomes to buffer moderate changes in membrane tension on a minute time scale. Meanwhile, a temporary reduction of the rate of endocytosis for 2 to 6 minutes, and an increase in the rate of exocytosis for at least 5 minutes allow cells to add large pools of membrane to the plasma membrane. We built on these results to submit the cells to abrupt increases in membrane tension and determine that the endocytic actin machinery of fission yeast cells rapidly adapts to perform clathrin-mediated endocytosis. Our study sheds light on the tight connection between membrane tension regulation, endocytosis and exocytosis.

    1. Cancer Biology
    2. Cell Biology
    Alvaro Gonzalez Rajal et al.
    Research Advance

    We previously used a pulse-based in vitro assay to unveil targetable signalling pathways associated with innate cisplatin resistance in lung adenocarcinoma (Hastings et al., 2020). Here we advanced this model system and identified a non-genetic mechanism of resistance that drives recovery and regrowth in a subset of cells. Using RNAseq and a suite of biosensors to track single cell fates both in vitro and in vivo, we identified that early S phase cells have a greater ability to maintain proliferative capacity, which correlated with reduced DNA damage over multiple generations. In contrast, cells in G1, late S or those treated with PARP/RAD51 inhibitors, maintained higher levels of DNA damage and underwent prolonged S/G2 phase arrest and senescence. Combined with our previous work, these data indicate that there is a non-genetic mechanism of resistance in human lung adenocarcinoma that is dependent on the cell cycle stage at the time of cisplatin exposure.